PURPOSE: To determine the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), and
pharmacodynamics (PD) of the proteasome inhibitor bortezomib (previously known as PS-…

Activation of seven-transmembrane (7TM) receptors by agonists does not always lead to
uniform activation of all signaling pathways mediated by a given receptor. Relative to other …

Purpose To determine the maximum-tolerated dose (MTD), efficacy, safety, and pharmacokinetics
of oblimersen sodium in patients with advanced chronic lymphocytic leukemia (CLL). …

Background Nilotinib inhibits the tyrosine kinase activity of ABL1/BCR-ABL1 and KIT,
platelet-derived growth factor receptors (PDGFRs), and the discoidin domain receptor. Gain-of-…

Purposes Pharmacologic downregulation of Bcl-2, an antiapoptotic protein overexpressed
in cancer, might increase chemosensitivity in acute myeloid leukemia (AML). Herein, we …

Purpose: While immune checkpoint inhibitors such as anti–PD-L1 are rapidly becoming the
standard of care in the treatment of many cancers, only a subset of treated patients have long…

Purpose: We evaluated the activity of AZD8205, a B7-H4–directed antibody–drug conjugate
(ADC) bearing a novel topoisomerase I inhibitor (TOP1i) payload, alone and in combination …

Reviews research on intimate partner violence in immigrant and refugee communities and
examines victims' needs, challenges for agencies, and promising practices for prevention …

Reports suggest that Alzheimer’s disease (AD) patients show a high life-time prevalence of
seizure-like disorders. The transgenic CRND8 (TgCRDN8) is a mouse model of AD-like …

Purpose Activating KIT mutations are part of the pathogenesis of systemic mastocytosis (SM).
Nilotinib is a tyrosine kinase inhibitor that potently inhibits activated forms of KIT. This …